An antibody-drug conjugate for ovarian cancer
Mirvetuximab soravtansine
A targeted antibody-drug conjugate used to treat some types of ovarian cancer, given as a drip into a vein.
What is Mirvetuximab soravtansine?
Mirvetuximab soravtansine is a specialist cancer medicine used to treat certain ovarian cancers that carry a marker called folate-receptor alpha and that have come back after earlier treatment. It is an antibody-drug conjugate, meaning an antibody is joined to a cell-killing payload so it can deliver that payload mainly to the cancer cells. It is given as a drip into a vein on a regular cycle under cancer specialists. The most important safety issue is eye problems, including blurred or changed vision and damage to the surface of the eye, so eye checks and lubricating drops are used. It can also affect the nerves and, less often, the lungs, and it can harm an unborn baby, so reliable contraception is essential.
Education and reference only. This is a plain-language guide to Mirvetuximab soravtansine — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Mirvetuximab soravtansine is a targeted cancer treatment known as an antibody-drug conjugate. It is made of an antibody that recognises folate-receptor alpha, a marker found on some ovarian cancer cells, joined to a powerful cell-killing payload. By delivering that payload mainly to cells carrying the marker, it aims to attack the cancer while sparing more healthy cells than older chemotherapy. It is used for certain ovarian, fallopian-tube or primary peritoneal cancers that have the marker and have returned after previous treatment. It is given as a drip into a vein, on a repeating cycle, under the care of a cancer team.
How it works
The antibody part of mirvetuximab soravtansine attaches to folate-receptor alpha on the surface of cancer cells. The cell then takes the whole medicine inside, where the cell-killing payload is released and disrupts the cancer cell's ability to divide, causing it to die. Because the payload is mainly delivered to cells carrying the marker, this targeted approach tries to focus the damage on the cancer. It is given in repeated cycles to keep pressure on the cancer over time, with the team checking how the cancer responds and watching closely for side effects, particularly affecting the eyes.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist cancer medicine used in the UK to treat certain types of ovarian cancer that carry a marker called folate-receptor alpha.
Practical use
How to take Mirvetuximab soravtansine
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a drip into a vein by your cancer team, on a repeating cycle, not as something you take at home.
- Use the lubricating eye drops exactly as advised and attend all your eye appointments, as eye problems are the main concern.
- Report any blurred vision, eye pain, dryness or change in sight straight away, as treatment may need adjusting.
- Tell your team about any new tingling, numbness or weakness in the hands or feet, or any breathlessness or cough.
- Use reliable contraception during treatment and for as long as your team advises, as it can harm an unborn baby.
Weighing it up
Advantages & disadvantages of Mirvetuximab soravtansine
Advantages
- A targeted treatment for ovarian cancers carrying the folate-receptor-alpha marker that have come back.
- Aims to deliver its cell-killing payload mainly to the cancer cells rather than throughout the body.
- Offers an option after other treatments, given on a planned cycle under specialist care.
Disadvantages
- Can cause eye problems, including blurred vision and damage to the surface of the eye, needing eye checks and drops.
- Can cause nerve effects such as tingling or numbness, and, less often, inflammation of the lungs.
- Given as a drip in hospital and can harm an unborn baby, so contraception is essential.
Practical use
Good to know
The most important thing to understand about mirvetuximab soravtansine is that it can affect the eyes, causing blurred vision, changes in sight, dry or gritty eyes and damage to the clear surface at the front of the eye. Because of this, you will usually have eye checks before and during treatment, be given lubricating eye drops to use regularly, and may be advised to avoid contact lenses for a time. Any new blurring, eye pain or change in vision should be reported promptly, as the dose may need to be adjusted or paused. It can also cause tingling, numbness or weakness in the hands and feet from nerve effects, and, less commonly, inflammation of the lungs that causes breathlessness or a cough, which needs urgent review. Like other cancer treatments of this kind, it can harm an unborn baby, so reliable contraception is essential during treatment and for a time afterwards, and it is given only under specialist cancer care.
Who should not take it / use with caution
- People who have had a serious allergic reaction to mirvetuximab soravtansine should not have it.
- It must not be used in pregnancy, as it can seriously harm an unborn baby; reliable contraception is needed.
- It is used with particular care, and extra eye monitoring, in people with existing eye problems, under specialist supervision.
Monitoring
- Eye checks before and during treatment, with lubricating drops and prompt review of any vision change.
- Watching for nerve symptoms and for signs of lung inflammation such as breathlessness or a cough.
- Regular blood counts and liver blood tests, and reviews of how the cancer is responding.
Side effects
- Eye problems such as blurred vision, dry or gritty eyes, sensitivity to light and damage to the surface of the eye.
- Tingling, numbness or weakness in the hands and feet, tiredness, nausea and diarrhoea.
- Less commonly, inflammation of the lungs causing breathlessness or a cough, which needs urgent review.
- Reactions during or after the drip, and changes in blood counts and liver blood tests.
Key interactions
- Tell your team about all your medicines, including eye drops and anything bought over the counter.
- Other treatments that affect the nerves or the eyes may add to those side effects.
- Vaccines and other cancer treatments should be coordinated by your specialist team.
Available as: A solution given as a drip into a vein in hospital.
Answers
Mirvetuximab soravtansine: frequently asked questions
What is mirvetuximab soravtansine used for?
It is used to treat certain ovarian, fallopian-tube or primary peritoneal cancers that carry the folate-receptor-alpha marker and have come back after earlier treatment.
Why do I need eye checks?
Its main safety concern is eye problems, including blurred vision and damage to the front of the eye, so eye checks and lubricating drops are used and any change in sight should be reported quickly.
How is it given?
It is given as a drip into a vein by your cancer team on a repeating cycle, not as a tablet or something taken at home.
Can it affect my nerves or lungs?
It can cause tingling, numbness or weakness in the hands and feet, and less commonly inflammation of the lungs causing breathlessness or a cough, which needs urgent review.
Is it safe in pregnancy?
No. It can seriously harm an unborn baby, so it must not be used in pregnancy and reliable contraception is essential during and after treatment.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.